Australie - anglais - Department of Health (Therapeutic Goods Administration)

austin health - injection, powder for - excipient ingredients: succimer; stannous chloride; ascorbic acid; inositol; hydrochloric acid; sodium hydroxide - diagnostic agent when radiolabelled for renal cortical scintigraphy

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (united states) - succimer - oral capsule - 100mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

curium pharma uk ltd - succimer - kit for radiopharmaceutical preparation - 1mg

Kenya - anglais - Pharmacy and Poisons Board

succimer - capsule - 100mg - antidotes

États-Unis - anglais - NLM (National Library of Medicine)

rotop pharmaka gmbh - 2,3-dimercaptosuccinic acid (unii: 4s9ju7xf01) (2,3-dimercaptosuccinic acid - unii:4s9ju7xf01) - 2,3-dimercaptosuccinic acid 1 mg - rotop - dmsa is a radiodiagnostic pharmaceutical. the kit contains the non-radioactive powder for reconstitution of the [99m tc]technetium succimer injection solution ([99m tc]-dmsa). the sodium [99m t]pertechnetat which is needed for the preparation is not part of this kit. after labelling with sodium [99m tc]technetium pertechnetat solution, rotop - dmsa is used for static renal scintigraphy when adequate diagnostics are not possible using other diagnostic procedures (such as ultrasound): - to identify focal renal parenchymal changes (e.g. in the case of renal infarction) - to identify norm variants such as atypical double kidney, small kidney, dysplastic kidney, horseshoe kidney, as well as to identify ectopic kidneys - to confirm absence of renal function in multicystic kidneys. take special care with rotop – dmsa rotop - dmsa is not suitable for determining global renal function from the dmsa accumulation. in the case of proximal tubulopathies [99m tc]dmsa does not lead to a sufficient diagnostic renal a

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

curium belgium s.p.r.l.-b.v.b.a. - succimer 1,2 mg - kit for radiopharmaceutical preparation - 1,2 mg - dimercaptosuccinic acid 1.2 mg - technetium (99mtc) succimer

Irlande - anglais - HPRA (Health Products Regulatory Authority)

cis bio international - dimercaptosuccinic acid - kit for radiopharmaceutical preparation - 1 mg - technetium (99mtc) compounds; technetium (99mtc) succimer

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ansto t/a ansto health - stannous chloride; succimer -

Israël - anglais - Ministry of Health

medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

ge healthcare limited - succimer - unknown